CellMax Life and TSH Biopharm Enter Into Distribution Partnership for Taiwan and ASEAN TSH Biopharm to make strategic investment in CellMax, becomes exclusive distributor in Taiwan for all CellMax's diagnostic tests
February 14, 2019 – Sunnyvale, CA – CellMax Life, a liquid biopsy company with a proprietary platform for detecting pre-cancer and cancer cells in blood, will be the first diagnostics partner for the TSH Biopharm (TWO: 8432) subsidiary company of TTY Biopharm (TWO: 4105), a public therapeutics company, ranked in the top 1 percent of largest biopharmaceutical companies in oncology in Taiwan. TSH Biopharm is making a strategic investment in CellMax Life and will be granted exclusive sales and distribution rights for all CellMax Life's diagnostics tests in Taiwan and non-exclusive in ASEAN, including its comprehensive liquid biopsy. CellMax Life offers the most prescribed liquid biopsy test in Taiwan. By combining the proprietary CTC CMx platform with the CellMax SMSEQ ctDNA based liquid biopsy platform, CellMax uniquely offers oncology diagnostic tests with CTC and ctDNA liquid biopsy technologies across the continuum of care."With personalized medicine solutions, cancer can be managed like a chronic disease, enhancing quality of life for patients, and positively impacting survival rates. Expansion into multi-analyte oncology diagnostics is one of the top strategic priorities for our company, driven by demand from oncologists, patients and consumers," said Sze Yuan Yang, new GM of TSH Biopharm. "We elected to partner with CellMax Life because they offer the most comprehensive menu of tests for cancer prevention, early-detection, treatment and monitoring. We were particularly impressed with the sensitivity of the CellMax Life circulating tumor cell platform CMx for the detection of colorectal cancer presented at ASCO's gastrointestinal symposium in 2019. Further, CellMax's CAP accredited Lab in Taiwan allows for a fast turnaround and local support." "There has been great advancement in the field of cancer treatment. In the last 5 years alone, the FDA has approved 15 immunotherapies and 2 CAR-T cell therapies," said Atul Sharan, Co- Founder and CEO of CellMax Life. "TSH and its parent company, TTY, are among the top Taiwanese specialty pharmaceutical companies with a strong portfolio of biodrugs and new chemical entities (NCE), as well as the largest physician channels targeting all major hospitals in Taiwan. We are very excited to partner with TSH Biopharm to offer an integrated diagnostics and therapy solution for cancer."
About CellMax Life CellMax Life is a liquid biopsy company with a proprietary platform for the detection of pre-cancer and colorectal cancer in a single blood sample. The company has a CLIA- & CAP-accredited lab in Sunnyvale, California and a CAP-accredited lab in Taipei, Taiwan. Visit https://cellmaxlife.com and https://tw.cellmaxlife.com/.
About TSH Biopharm TSH Biopharm Co., Ltd. was one of the business units of TTY Biopharm and formed in 2003, later spin-off from TTY Biopharm in late 2010. Since its spin-off, TSH Biopharm has been dedicated to the drug development of chronic disease as well as the marketing of specialty drugs in Taiwan and ASEA. Visit.
Media Contact: Jackie Copp
Pitch Public Relations™
Jackie@PitchPublicRelations.com
480.606.8180
東生華製藥(8432)於今日(2/13)下午公告策略性投資美商CellMax Cayman，並與旗下CellMax Life(合度精密生物科技有限公司，以下簡稱CellMax Life)簽訂經銷合約，以取得CellMax Life所有液態切片檢測產品及後續新產品於台灣、東南亞、韓國之代理權及中國大陸地區之優先承購權。CellMax Life是一家專注於液態切片，擁有檢測血液中癌症前期和癌症細胞專有平台的公司，CellMax Life的液態切片檢測為全台最多人使用的液體切片，通過其專利的CTC CMx平台，以及用以分析ctDNA的獨家SMSEQ次世代定序平台相結合，CellMax Life提供了在不同癌症時期的全方位腫瘤診斷檢測。昔日著重於心血管、腸胃及自體免疫疾病藥品開發與行銷的東生華，在新任總經理楊思源的帶領下，將慢性疾病領域之核心專長擴大至重症慢性疾病，跨足Critical Patient Care，致力於提升慢性病患者及慢性重症患者之生活品質。於母公司台灣東洋藥品(4105)累積近20年癌症領域市場開發與行銷經驗的楊思源總經理表示＂透過個人化醫療解決方案，癌症可以如慢性病般管理，並在精準醫療照護下，更能提高癌症患者的生活品質；東生華選擇與CellMax Life合作，因為他們提供癌症預防、早期檢測、治療效果監測等全方位檢測服務。東生華對CellMax Life在2019年ASCO胃腸道研討會上提出其循環腫瘤細胞平台CMx運用CTC技術檢測大腸直腸癌的敏感度留下特別深刻的印象，而CellMax Life在台灣設置的亞洲區唯一CAP認證實驗室更能迅速提供專業的檢驗結果予國人。在腫瘤學家、患者及消費者的醫療需求下，擴展到多重分析腫瘤預防與診斷是東生華首要戰略重點之一。＂隨著高齡化社會的來臨，精準醫療技術亦日益精進，包含心臟血管、免疫失調、癌症、老化等，讓慢性疾病的治療不再是遙不可及的夢想；此次東生華與CellMax Life策略合作，取得CellMax Life產品於台灣獨家、東南亞與韓國非專屬代理權，以及中國大陸地區之優先承購權，讓東生華正式跨足精準醫療領域，提供健康國人基因檢查、癌症病患液態細胞與基因檢查之全方位檢測服務，以實踐做對國人健康管理有意義的事情。此外，東生華啟動雙引擎策略，除引進創新治療領域產品外，將持續開發心血管及自體免疫藥品，如治療骨質疏鬆症之生物相似性藥品TRIA及治療心絞痛之RNTA，同時加速驅動國際事業發展策略，增加與全球各地生技公司策略聯盟，擴大東生華之產品組合並跨足國際。
No comments:
Post a Comment